Compare TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $243.75 (market cap $46.84B), while Vertex Pharmaceuticals Incorporated trades at $527.25 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.9× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals.
| TTWO | VRTX | |
|---|---|---|
Market Cap | $46.84B | $134.25B |
Sector | Media | Health |
52-Week High | $262.29 | $529.65 |
52-Week Low | $189.69 | $376.62 |
Enterprise Value | $47.96B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Take-Two Interactive (TTWO) trades at $253.57, up 2.87% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters despite a net loss, driven by NBA 2K and Grand Theft Auto (GTA) performance. Cash flow improved in 2025 due to financing activities, while debt levels remain elevated. Investor focus centers on the November 2026 GTA VI launch, with preorders termed 'unprecedented' by management (Bloomberg, August 7, 2026).
The outlook hinges on GTA VI's success, offering substantial upside to the $300.55 consensus target, but execution risks and high valuation multiples (P/S 6.94, EV/EBITDA 38.35) warrant caution. Near-term volatility may persist amid earnings uncertainty, though institutional bullishness (78.95% buy ratings) underscores long-term growth potential.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
